Monday broker round-up
28th Jun 2021 13:28
(Sharecast News) - St James Place: HSBC downgrades to hold with a target price of 1,525p.
Read moreAstraZeneca's Forxiga recommended for EU approval
28th Jun 2021 07:47
(Sharecast News) - AstraZeneca said on Monday that 'Forxiga', or dapagliflozin, has been recommended for approval in the European Union for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
Read moreAstraZeneca, MSD prostate cancer drug gets China green light
24th Jun 2021 07:34
(Sharecast News) - AstraZeneca and MSD's Lynparza prostate cancer drug has been granted conditional approval in China after a successful phase three trial, the companies said on Thursday.
Read moreWednesday broker round-up
23rd Jun 2021 13:04
(Sharecast News) - Hunting: JP Morgan upgrades overweight with a target price of 290p.
Read moreDelta plus variant reclassified as 'variant of concern', experts sanguine for now
23rd Jun 2021 10:47
(Sharecast News) - India's Health Ministry has upgraded a new variant of Covid-19 dubbed Delta plus to a "variant of concern".
Read moreAstraZeneca's 'Orpathys' gets conditional approval in China
23rd Jun 2021 07:33
(Sharecast News) - AstraZeneca announced on Wednesday that 'Orpathys', or savolitinib, has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC), with MET exon 14 skipping alterations who have progressed following prior systemic therapy or were unable to receive chemotherapy.
Read moreAstraZeneca given EU approval for use of Koselugo in children
22nd Jun 2021 08:25
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo drug had been approved for use in children with neurofibromatosis type 1 and plexiform neurofibromas across the European Union.
Read moreThursday broker round-up
17th Jun 2021 13:49
(Sharecast News) - Pets At Home: Liberum upgrades to buy with a target price of 510p.
Read moreWednesday broker round-up
16th Jun 2021 12:50
(Sharecast News) - Pets At Home: Berenberg reiterates buy with a target price of 540p.
Read moreTuesday broker round-up
15th Jun 2021 13:39
(Sharecast News) - Page Group: Morgan Stanley downgrades to underweight with a target price of 545p.
Read moreAstraZeneca antibody fails to prevent Covid in exposed patients
15th Jun 2021 07:45
(Sharecast News) - AstraZeneca said a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic Covid-19 in people exposed to the coronavirus in the past eight days.
Read moreTuesday broker round-up
8th Jun 2021 13:54
(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.
Read moreMonday broker round-up
7th Jun 2021 12:58
(Sharecast News) - Sainsbury's: Jefferies downgrades to hold with a target price of 280p.
Read moreNetScientific subsidiary strikes exclusive licensing deal with AstraZeneca
7th Jun 2021 09:38
(Sharecast News) - Life sciences investment company NetScientific announced on Monday that its subsidiary ProAxsis has entered into an exclusive licensing agreement with AstraZeneca.
Read moreNew data confirms AstraZeneca's confidence in Calquence
7th Jun 2021 07:38
(Sharecast News) - AstraZeneca said on Monday that final results from the head-to-head 'ELEVATE-RR' phase 3 trial of 'Calquence', or acalabrutinib, demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in adults with previously-treated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.
Read more